Table 4. Interaction between S100P expression with p53 mutation or β-catenin mutation in the tumor progression of hepatocellular carcinoma.

Feature	S100P expression/p53 mutation
	Yes/Yes	Yes/No	No/Yes	No/No	P value
Stage
I	7 (12%)a	23 (47%)	9 (35%)	30 (56%)a	0.0000115
II–III	51 (88%)b,	26 (53%)b	17 (65%)	24 (44%)
ETR†
Presence	35 (69%)c	13 (33%)c	7 (32%)	17 (35%)	0.00051
Absence	16 (31%)d	27 (67%)	15 (68%)	32 (65%)d
	S100P expression/β-catenin mutation
	Yes/Yes	Yes/No	No/Yes	No/No	P value
Stage
I	7 (54%)e	27 (25%)e	15 (79%)	28 (38%)	0.0000446
II–III	6 (46%)	81 (75%)f	4 (21%)f	46 (62%)
ETR†
Presence	2 (22%)	53 (57%)g	2 (12%)g	26 (40%)	0.00142
Absence	7 (78%)h	40 (43%)h	15 (88%)	39 (60%)

Abbreviations: NS, not significant; ETR, early tumor recurrence.

^†Tumor recurrence within 12 months after hepatectomy.

a, b, c, d, e, f, g and h designate comparison between the indicated two groups.

P values: ^a0.000001; ^b0.00006; ^c0.0006; ^d0.00068; ^e0.0288; ^f0.000004; ^g0.0015; ^h0.0457.